Trial Profile
Comparison of Sitagliptin vs Conventional therapy On Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2015
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Coronary arteriosclerosis; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SCOOP
- 12 Jul 2013 Planned End Date changed from 1 Mar 2014 to 31 Mar 2015 as reported by University Hospital Medical Information Network - Japan.
- 24 Aug 2012 Planned End Date added to 1 Mar 2014 as reported by University Hospital Medical Information Network - Japan.
- 06 Jun 2012 New trial record